Position in TNGX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$4,646,562
New position
Shares Held
222,111
first reported quarter
Ownership
0.154%
of shares outstanding
% of Portfolio
0.31%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cinctive Capital Management LP holds $185,949,026 across 51 Biotechnology names. TNGX ranks #15 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
73,063 | $11,947,261 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
145,728 | $10,821,761 | |
| 3 | NTHI |
Neonc Technologies Holdings, Inc.
|
1,425,526 | $9,992,937 | |
| 4 | DAWN |
Day One Biopharmaceuticals, Inc.
|
450,000 | $9,648,000 | |
| 5 | ACLX |
Arcellx, Inc.
|
80,000 | $9,185,600 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
93,857 | $9,127,593 | |
| 7 | SRRK |
Scholar Rock Holding Corp
|
172,535 | $8,481,820 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
15,326 | $8,022,701 |
All Filings in TNGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,646,562 | 222,111 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||